Atliprofen (previously known as IDPH 8261), a nonsteroidal anti-inflammatory cyclooxygenase inhibitor was developed as an anti-inflammatory drug. Low toxicity and high efficacy allowed making this compound a potentially useful therapeutic agent. IDPH 8261 participated in the clinical trial phase III in India for the treatment of rheumatic disorders However, information about the further development of the drug is not available.

Asimadoline is an orally active, highly selective kappa-opioid receptor agonist with approximately 500-fold greater affinity for human kappa-, as compared with either delta- or mu-opioid receptors. Due to its high selectivity for the kappa-opioid receptor, asimadoline does not produce mu-opioid like side effects. It is investigated for use/treatment in irritable bowel syndrome, pruritus, postoperative ileus. A drug interaction study investigating the coadministration of asimadoline with ketoconazole was performed in healthy volunteers - a two to three-fold increase in AUC and Cmax of asimadoline was observed with concomitant administration of ketoconazole. The most common adverse events are diarrhea, nausea, sinusitis, headache and fatigue.

Aclantate is a nonsteroidal anti-inflammatory drug.

Atrasentan (ABT-627, A-127722) is a selective endothelin A receptor antagonist. Atrasentan is being developed by AbbVie as an oral treatment for diabetic nephropathies.Abbott Laboratories was conducting clinical development of atrasentan for the treatment of certain cancers, including phase II trials for prostate cancer. However, no recent development has been reported for cancer indications and development is presumed to be discontinued.

FILENADOL is an analgesic drug with antinociceptive and anti-inflammatory properties. It reduces the hyperalgesic effects of inflammatory mediators besides inhibiting partially the synthesis of eicosanoids.

PF-03463275 is the novel azabicyclic glycine transporter 1 (GlyT1) inhibitor. Ketamine induced hallucinatory-like behaviors that were not reversed by PF-3463275. In contrast, all doses of PF-3463275 alleviated the deficit in spatial working memory induced by ketamine. PF-03463275 causes changes in electroretinogram (ERG) responses in albino rats. There was dose-dependent reduction in the amplitude of the rat ERG oscillatory potentials (OPs) following single subcutaneous administrations of the PF-03463275. Furthermore, the amplitude of OPs was negatively correlated to the concentration of PF-03463275 in the vitreous humor collected from rats immediately following ERG recordings. A slight increase in the amplitude and latency of the a-wave component of the ERG with PF-03463275 treatment was observed. Since the ERG changes occur in our rodent model with PF-03463275 at exposures comparable with those associated with visual disturbance in the clinic, it was proposed that the visual adverse effects reported in healthy volunteers treated with selective GlyT1 inhibitors may represent a retinal class effect. The dose-related GlyT1 occupancy of PF-03463275 is linear. While PF-03463275 did not show evidence of facilitating N-methyl-D-aspartate receptor function in the ketamine assay, it enhanced neuroplasticity in schizophrenia patients. PF-03463275 had been in phase II clinical trial for the treatment of schizophrenia. However, this development was discontinued.

Mesabolone is a synthetic anabolic androgen.

FLUCETOREX is a substituted amphetamine with anorectic activity.

FLUALAMIDE is an antiemetic agent.